CM
AVDL

Caption Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Caption Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-24,000
Closed -$517K – 1551
2025
Q4 		$517K Buy
+24,000
New +$466K ﹤0.01% 1236
2025
Q1 		– Sell
-160,000
Closed -$1.68M – 1509
2024
Q4 		$1.68M Buy
160,000
+102,500
+178% +$1.24M 0.02% 756
2024
Q3 		$754K Sell
57,500
-7,100
-11% -$108K 0.01% 846
2024
Q2 		$908K Buy
+64,600
New +$1.05M 0.01% 690
2023
Q1 		– Sell
-55,000
Closed -$394K – 1085
2022
Q4 		$394K Buy
+55,000
New +$386K 0.01% 969
2022
Q1 		– Sell
-73,900
Closed -$597K – 1451
2021
Q4 		$597K Sell
73,900
-501,100
-87% -$4.58M 0.01% 1209
2021
Q3 		$5.63M Buy
575,000
+550,000
+2,200% +$4.33M 0.06% 407
2021
Q2 		$168K Buy
+25,000
New +$199K ﹤0.01% 1191
2020
Q3 		– Sell
-50,000
Closed -$405K – 1028
2020
Q2 		$405K Sell
50,000
-367,200
-88% -$3.24M 0.01% 708
2020
Q1 		$3.31M Buy
+417,200
New +$3.2M 0.19% 157

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Caption Management's AVDL Position: Q1 2026 in Review

Caption Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 536,838 shares — an estimated $11.6M sold.

Caption Management first reported a position in AVDL in Q3 2020 and held it in 16 quarters. The position peaked at $11.6M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Caption Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Caption Management sold 536,838 Avadel Pharmaceuticals shares in Q1 2026, an estimated $11.6M.
  • Caption Management first reported a position in Avadel Pharmaceuticals in Q3 2020 and held it in 16 quarters.
  • Caption Management's Avadel Pharmaceuticals position peaked at $11.6M in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.